Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 15.55% is in line with its 5-year average of 14.91%, around the middle of its 5-year range (13.26%–17.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.22% above its 12-month average of 14.36%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 15.55%.
RETURN ON EQUITY (ROE)
15.55%
RETURN ON EQUITY (ROE) AVG TTM
14.36%
RETURN ON EQUITY (ROE) AVG 3Y
15.37%
RETURN ON EQUITY (ROE) AVG 5Y
14.91%
RETURN ON EQUITY (ROE) AVG 10Y
14.70%
RETURN ON EQUITY (ROE) AVG 15Y
14.37%
RETURN ON EQUITY (ROE) AVG 20Y
15.54%
CURRENT VS TTM AVG
+8.22%
CURRENT VS 3Y AVG
+1.12%
CURRENT VS 5Y AVG
+4.28%
CURRENT VS 10Y AVG
+5.76%
CURRENT VS 15Y AVG
+8.14%
CURRENT VS 20Y AVG
+0.01%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+19.49%
vs the sector median at left
Stryker Corporation
Market Cap
$108.06B
Return on Equity (ROE)
15.55%
TTM Avg
14.36%
3Y Avg
15.37%
5Y Avg
14.91%
Market Cap
$106.65B
Return on Equity (ROE)
N/A
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$120.07B
Return on Equity (ROE)
10.41%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$121.92B
Return on Equity (ROE)
6.16%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$92.12B
Return on Equity (ROE)
N/A
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$92.00B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$130.94B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stryker Corporation (SYK) | $108.06B | 15.55% | 14.36% | 15.37% | 14.91% |
| McKesson Corporation (MCK)vs › | $106.65B | N/A | -189.06% | -180.53% | 3473.86% |
| Sanofi (SNY)vs › | $104.04B | 5.82% | 9.06% | 9.15% | 10.86% |
| GSK plc (GSK)vs › | $100.28B | 27.67% | 26.90% | 55.97% | 45.70% |
| Medtronic plc (MDT)vs › | $120.07B | 10.41% | 9.71% | 8.51% | 8.44% |
| CVS Health Corp. (CVS)vs › | $121.92B | 6.16% | 4.23% | 6.35% | 7.74% |
| HCA Healthcare, Inc. (HCA)vs › | $92.12B | N/A | -171.53% | -210.62% | -155.29% |
| Elevance Health Inc. (ELV)vs › | $92.00B | 11.06% | 13.69% | 14.71% | 14.93% |
| Bristol-Myers Squibb Company (BMY)vs › | $130.94B | 41.59% | -8.30% | 7.76% | 4.45% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $131.85B | 21.76% | 8.96% | 15.60% | 19.47% |
ROE
15.5%
ROA
7.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 15.55% |
| 2026-03-31 | 14.52% |
| 2025-12-31 | 14.48% |
| 2025-09-30 | 13.51% |
| 2025-06-30 | 13.77% |
| 2025-03-31 | 13.66% |
| 2024-12-31 | 14.51% |
| 2024-09-30 | 17.82% |
| 2024-06-30 | 17.45% |
| 2024-03-31 | 17.53% |
| 2023-12-31 | 17.02% |
| 2023-09-30 | 14.44% |
| 2023-06-30 | 15.60% |
| 2023-03-31 | 15.55% |
| 2022-12-31 | 14.19% |
| 2022-09-30 | 14.92% |
| 2022-06-30 | 13.26% |
| 2022-03-31 | 13.39% |
| 2021-12-31 | 13.40% |
| 2021-09-30 | 13.40% |
| 2021-06-30 | 15.07% |
| 2021-03-31 | 10.43% |
| 2020-12-31 | 12.22% |
| 2020-09-30 | 13.52% |
| 2020-06-30 | 12.55% |
| 2020-03-31 | 16.50% |
| 2019-12-31 | 16.26% |
| 2019-09-30 | 27.82% |
| 2019-06-30 | 29.72% |
| 2019-03-31 | 30.12% |
| 2018-12-31 | 30.29% |
| 2018-09-30 | 12.54% |
| 2018-06-30 | 11.42% |
| 2018-03-31 | 11.06% |
| 2017-12-31 | 10.23% |
| 2017-09-30 | 17.06% |
| 2017-06-30 | 16.94% |
| 2017-03-31 | 17.41% |
| 2016-12-31 | 17.25% |
| 2016-09-30 | 17.78% |
| 2016-06-30 | 17.64% |
| 2016-03-31 | 18.36% |
| 2015-12-31 | 16.91% |
| 2015-09-30 | 13.87% |
| 2015-06-30 | 10.97% |
| 2015-03-31 | 9.09% |
| 2014-12-31 | 7.00% |
| 2014-09-30 | 8.44% |
| 2014-06-30 | 8.52% |
| 2014-03-31 | 8.52% |
| 2013-12-31 | 11.12% |
| 2013-09-30 | 10.19% |
| 2013-06-30 | 13.25% |
| 2013-03-31 | 14.81% |
| 2012-12-31 | 15.10% |
| 2012-09-30 | 17.09% |
| 2012-06-30 | 17.64% |
| 2012-03-31 | 17.30% |
| 2011-12-31 | 17.51% |
| 2011-09-30 | 16.40% |
| 2011-06-30 | 16.06% |
| 2011-03-31 | 16.88% |
| 2010-12-31 | 17.74% |
| 2010-09-30 | 17.57% |
| 2010-06-30 | 17.43% |
| 2010-03-31 | 17.21% |
| 2009-12-31 | 16.79% |
| 2009-09-30 | 16.75% |
| 2009-06-30 | 18.55% |
| 2009-03-31 | 20.24% |
| 2008-12-31 | 21.23% |
| 2008-09-30 | 19.95% |
| 2008-06-30 | 17.71% |
| 2008-03-31 | 21.99% |
| 2007-12-31 | 23.35% |
| 2007-09-30 | 23.40% |
| 2007-06-30 | 24.28% |
| 2007-03-31 | 19.40% |
| 2006-12-31 | 18.52% |
| 2006-09-30 | 18.40% |
| 2006-06-30 | 17.72% |
| 2006-03-31 | 18.11% |
| 2005-12-31 | 20.21% |
| 2005-09-30 | 20.37% |
| 2005-06-30 | 17.67% |
| 2005-03-31 | 17.37% |
| 2004-12-31 | 16.92% |
| 2004-09-30 | 17.46% |
| 2004-06-30 | 21.54% |
| 2004-03-31 | 21.21% |
| 2003-12-31 | 21.05% |
| 2003-09-30 | 21.79% |
| 2003-06-30 | 21.46% |
